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background:  Biodegradable polymer drug-eluting stent (BP-DES) reduced the risk of stent thrombosis (ST) compared with first-
generation durable polymer (DP)-DES. Limited data are available comparing second-generation (2G) DP-DES with BP-DES in patients 
with acute myocardial infarction (AMI).
methods:  A total of 3,207 AMI patients received either 2G DP-DES (n=2,965) or BP-DES (n=242) were included from Korea Acute 
Myocardial Infarction Registry (KAMIR) between January 2008 and May 2012. To adjust baseline characteristics, a 1:5 propensity score 
matching (PSM) was performed (1,210 patients for 2G DP-DES and 242 patients for BP-DES). The primary end point was the incidence of 
major adverse cardiac events (MACE) including all-cause death, recurrent myocardial infarction (re-MI), and target vessel revascularization 
(TVR). The rate of definite or probable ST was also investigated.
Results:  After PSM, there was no difference of baseline characteristics between the 2 groups. Two-year MACE was not different between 
the 2 groups (3.8% vs. 4.1%, p=0.910). The incidence of ST was also not different (1.0% vs. 0.4%, p=0.514). By multivariate analysis, age, 
diabetes mellitus, post-procedural TIMI flow were the independent predictors of MACE.
conclusion:  2G DP-DES has comparable safety and efficacy for AMI patients compared with BP-DES up to 2 years follow-up. However, 
longer-term follow-up will be needed to evaluate the difference of each polymer in this patient subset.
Two-year clinical events between 2G DP-DES and BP-DES
Event 2G DP-DES (n=1,210) BP-DES (n=242) P-value
MACE (%) 46 (3.8) 10 (4.1) 0.910
Death (%) 13 (1.1) 2 (0.8) 0.790
Re-MI (%) 14 (1.2) 3 (1.2) 0.841
TVR (%) 22 (1.8) 5 (2.1) 0.843
ST (%) 12 (1.0) 1 (0.4) 0.514
